MARKET

LGNYZ

LGNYZ

Ligand Pharma
OTCPK
0.048
-0.006
-11.11%
Closed 09:41 07/24 EDT
OPEN
0.048
PREV CLOSE
0.054
HIGH
0.048
LOW
0.048
VOLUME
10.00K
TURNOVER
480
52 WEEK HIGH
0.083
52 WEEK LOW
0.023
MARKET CAP
--
P/E (TTM)
0.0065
1D
5D
1M
3M
1Y
5Y
1D
Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Seeking Alpha · 02/26 22:48
Weekly Report: what happened at LGNYZ last week (0908-0912)?
Weekly Report · 09/15/2025 11:19
Weekly Report: what happened at LGNYZ last week (0901-0905)?
Weekly Report · 09/08/2025 11:22
Weekly Report: what happened at LGNYZ last week (0825-0829)?
Weekly Report · 09/01/2025 11:16
Weekly Report: what happened at LGNYZ last week (0818-0822)?
Weekly Report · 08/25/2025 11:28
Weekly Report: what happened at LGNYZ last week (0811-0815)?
Weekly Report · 08/18/2025 11:19
Weekly Report: what happened at LGNYZ last week (0804-0808)?
Weekly Report · 08/11/2025 11:27
Ligand raises 2025 revenue and EPS guidance to $225M and $7 amid royalty portfolio momentum
Seeking Alpha · 08/08/2025 00:02
More
About LGNYZ
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.

Webull offers Ligand Pharmaceuticals Inc stock information, including OTCPK: LGNYZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGNYZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGNYZ stock methods without spending real money on the virtual paper trading platform.